Abstract: OBJECTIVE: Systemic sclerosis-associated pulmonary arterial hypertension differs from idiopathic pulmonary arterial hypertension with respect to histopathology, treatment responses and survival. Medical progress on PAH is hampered by the lack of human biosamples and suitable animal models. In this study, the authors evaluated fos-related antigen 2 (Fra-2) transgenic mice as a novel model for systemic sclerosis-associated pulmonary arterial hypertension.METHODS: Lung sections of Fra-2 transgenic (n=12) and wild-type mice (n=6) were analysed at 16 weeks by histology using Dana Point criteria. Cellular and molecular key players were assessed by immunohistochemistry. To test the model's sensitivity to change over treatment, a subgroup of Fra-2 transgenic mice (n=6) was treated with the tyrosine kinase inhibitor nilotinib twice daily 37.5 mg orally from 8 weeks of age.RESULTS: Fra-2 transgenic mice developed severe vascular remodelling of pulmonary arteries and non-specific interstitial pneumonia-like interstitial lung disease resembling human systemic sclerosis-associated pulmonary hypertension. Histological features typical for systemic sclerosis-associated pulmonary arterial hypertension, such as intimal thickening with concentric laminar lesions, medial hypertrophy, perivascular inflammatory infiltrates, adventitial fibrosis, but not pulmonary occlusive venopathy were frequently detected. Platelet-derived growth factor signalling pathways were activated in pulmonary vessels of Fra-2 transgenic compared with wild-type mice. Since treatment with nilotinib strongly prevented the development of proliferative vasculopathy and lung fibrosis, the model proved to be sensitive to treatment.CONCLUSIONS: This study suggests that Fra-2 transgenic mice as an animal model of systemic sclerosis-associated pulmonary arterial hypertension display main characteristic features of the human disease. It therefore allows studying pathophysiological aspects and might serve as a preclinical model for interventional proof-of-concept studies. 
Abstract Objectives
Systemic sclerosis-associated pulmonary arterial hypertension differs from idiopathic pulmonary arterial hypertension regarding histopathology, treatment responses and survival. Progress is hampered by the lack of human biosamples and suitable animal models. Herein, we evaluated Fra-2 transgenic mice as a novel model for systemic sclerosis-associated pulmonary arterial hypertension.
Methods
Lung sections of Fra-2 transgenic (n=12) and wildtype mice (n=6) were analyzed at 16 weeks by histology using Dana Point criteria. Cellular and molecular key players were assessed by immunohistochemistry. To test the model's sensitivity to change over treatment, a subgroup of Fra-2 transgenic mice (n=6) was treated with the tyrosine kinase inhibitor nilotinib at 2x 37.5mg/d p. o. from 8 weeks of age.
Results
Fra-2 transgenic mice developed severe vascular remodeling of pulmonary arteries and nonspecific interstitial pneumonia-like interstitial lung disease resembling human systemic sclerosis-associated pulmonary hypertension. Histological features typical for systemic sclerosis-associated pulmonary arterial hypertension such as intimal thickening with concentric laminar lesions, medial hypertrophy, perivascular inflammatory infiltrates, adventitial fibrosis, but not pulmonary occlusive venopathy were frequently detected. Platelet-derived growth factor signaling pathways were activated in pulmonary vessels of Fra-2 transgenic compared to wildtype mice. Since treatment with nilotinib strongly prevented the development of proliferative vasculopathy and lung fibrosis, the model proved to be sensitive to treatment.
Conclusions
Our study suggests Fra-2 transgenic mice as an animal model of systemic sclerosisassociated pulmonary arterial hypertension that displays main characteristic features of the human disease. It therefore allows studying pathophysiological aspects and might serve as a preclinical model for interventional proof of concept studies.
To date, pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) account for more than 60% of the SSc-related mortality (1).
Patients with SSc-PAH have a worse prognosis and response to PAH-specific therapies than patients with idiopathic PAH (IPAH) or PAH related to other connective tissue diseases (2-4). The observed differences in SSc-PAH and the frequent co-existence of ILD (5) support the concept of a specific pathophysiology of SSc-related pulmonary hypertension (PH), and two recent studies suggested remarkable histopathological differences of the vascular lesions associated with IPAH and those related to SSc-PAH (6, 7).
Since research is hampered by the lack of human biosamples, animal models are of outmost importance to 1) study pathophysiological interactions between the different lung manifestations, to 2) identify molecular key players and potential therapeutic targets and 3) for preclinical proof of concept studies. Unfortunately, there is a shortage of validated animal models of SSc that simultaneously display features of ILD and pulmonary vasculopathy (8) , whereas established animal models of PAH rather reflect features of human IPAH than SSc-PAH (9).
The Fra-2 (Fos-related antigen-2) transgenic (tg) mouse model combines vasculopathy with fibrosis of the skin and internal organs, and Fra-2 protein is overexpressed in the skin and lungs of patients with SSc (10, 11) . The aim of our study was to analyze Fra-2 tg mice as a potential animal model of SSc-PH (1) by exploring whether it displays the histopathological features considered specific for SSc-PAH, (2) by characterizing key cellular and molecular pathways contributing to the SSc-PAH specific features and (3) by assessing its sensitivity to change over treatment.
Materials and Methods
Additional information on methods is provided in the online Data Supplement.
Animals
A subgroup of Fra-2 tg mice (10, 11) (n=6) was treated with nilotinib 2x37.5 mg/d and compared to vehicle-treated Fra-2 tg mice and wildtype (wt) littermates (n=6 each). Fra-2 tg mice were backcrossed from a mixed (C57BL/6×CBA) genetic background on a pure C57/Bl6 background for at least six generations (11) .
Histology
Lung sections were prepared as described previously (12) . Sections were stained with hematoxylin and eosin (HE) and Masson's trichrome staining according to standard protocols.
Immunohistochemistry
For primary and secondary antibodies refer to data supplement.
Analysis of histological and immunohistochemical stainings
All slides were analyzed by two blinded independent examiners. Pictures were taken with a digital camera on an Imager1 microscope (Carl-Zeiss AG, Feldbach, Switzerland), using AxioVision software Release 4.6.
Pulmonary histopathology was assessed by microscopic criteria including pattern and distribution of inflammation, deposition of extracellular matrix, and architectural changes (13) . Vascular histopathology was analyzed according to the Dana point consensus criteria (14) . 
Statistical analysis
Nonparametric nonrelated data were analyzed with the Mann-Whitney-U test and expressed as median (Q1,Q3) . P-values<0.05 were considered statistically significant. Power calculation was performed using STATA 10.0 (StataCorp, College Station, Texas).
Results

Pulmonary pathology of Fra-2 tg mice resembles changes in SSc-PH
Pulmonary vasculopathy
To investigate Fra-2 tg mice as a potential model for SSc-PAH, we analyzed features of pulmonary vascular remodeling.
Increase in wall thickness and occlusion of pulmonary arteries were the most prominent features of pulmonary pathology in Fra-2 tg (Fig.1B ) compared to wt mice (Fig.1A) . Semiquantitative analysis of vascular remodeling showed that in Fra-2 tg mice the thickness of vessel walls was strongly increased compared to wt mice (median (Q1,Q3) 44 (32,59) μm vs. 21.5 (13, 36) μm; p<0.0001) (Fig.1C) . Obliterated vessels were almost undetectable in wt mice (0 (0,1) %), whereas the percentage of obliterated vessels was increased to 33 (33,53) % in Fra-2 tg mice (p=0.04) (Fig.1D ).
We next evaluated the histopathology of pulmonary vessels according to the DANA point criteria (14) (table 1). In summary, Fra-2 tg mice developed several features that are considered more common in SSc-PAH than in IPAH. In contrast to human SSc-PH, pulmonary occlusive venopathy (POV, formerly PVOD) was not detectable in Fra-2 tg mice.
Interstitial lung disease
Given the frequent co-existence of ILD, we additionally examined the histology of interstitial lung changes (for details refer to data supplement).
In summary, Fra-2 tg mice developed a severe interstitial pneumonitis and fibrosis with concomitant lung emphysema (suppl. Fig.1 ) which closely resembled the features of human nonspecific interstitial pneumonia (NSIP), which is the main histological pattern in SSc-ILD (15) . In contrast to a previous study (10) , honeycombing, severe scarring or other pulmonary changes resembling human UIP
were not observed which might be due to the different genetic background of the Fra-2 tg mice.
Cellular composition of intimal lesions
We next characterized the cells driving the intimal thickening in Fra-2 tg mice.
In wt mice, α-SMA (smooth muscle antigen) staining indicated muscular pulmonary vessels ( Fig.2A) . α-SMA+ myofibroblasts/vascular smooth muscle cells (VSMCs) (Fig.2B) were the most abundant cells within the neointima, whereas expansion of endothelial cells (van Willebrand factor (vWF)+) was not observed (Fig.2B) . To differentiate between VSMCs and myofibroblasts, we performed additional stainings with antibodies against the VSMC-specific marker SM22α (smooth muscle 22α) (Figs.2C+D) . In wt mice, VSMCs were mainly found within the walls of bronchi (Fig.2C) , in Fra-2 tg mice, mainly in the media but not the intima of pulmonary vessels and in bronchiolar walls (Fig.2D) .
The proliferation marker PCNA (proliferating cell nuclear antigen) (Figs.2E+F) was abundantly expressed by myofibroblasts showing that the observed changes were due to proliferation and not hypertrophy of cells.
In summary, mainly myofibroblasts and to a lesser extent VSMCs were key players in the remodeling of pulmonary arteries in Fra-2 tg mice which differs from the previous finding of VSMCs as the most abundant cells. This difference might either be due to technical reasons (no additional staining with a VSMC-specific marker such as SM22α+) or due to the different genetic background of the Fra-2 tg mice.
Molecular mechanisms of vascular remodeling: PDGF signaling
Next, we assessed potential molecular mechanisms of both vasculopathy and ILD. In patients with IPAH, PDGF-BB has been proposed as a novel therapeutic target (16, 17) , and a recent study reported a higher immunoreactivity for p-PDGFRβ in SSc-PAH compared to IPAH (18) .
Thus, we analyzed the expression of PDGF-BB and the phosphorylated (=activated) PDGFRβ in the lungs of Fra-2 tg and wt mice by assessing the staining intensity. Both, the expression of PDGF-BB (Fig.3B ) and of p-PDGFRβ (Fig.3E ) was increased in vascular structures of Fra-2 tg compared to wt mice (Figs.3A+D) .
Occasionally, increased staining for p-PDGFRβ could be observed in the alveolar epithelium of Fra-2 tg mice (Fig.3E) . Semiquantitative analysis confirmed the substantially increased expression of PDGF-BB in pulmonary vessels in Fra-2 tg compared to wt mice (median (Q1,Q3) of staining intensity 3 (2.8,3.0) vs. 0 (0,1) ; p<0.0001) (Fig.3C) . A similarly strong upregulation was observed for p-PDGFRβ (3 (2, 3) vs. 0 (0.0,0.3); p<0.0001) (Fig.3F) . In addition to vascular structures, tissue macrophages (F4/80+) in Fra-2 tg mice showed a strong upregulation of both PDGF-BB (Fig.3G) and p-PDGFRβ (Fig.3H) . These findings suggest a potential role for PDGF-BB in the pulmonary pathophysiology of Fra-2 tg mice.
Nilotinib prevents vascular remodeling and fibrosis in Fra-2 tg mice
Next we evaluated whether targeting the PDGF-BB/PDGFR pathway using the tyrosine kinase inhibitor nilotinib could modify the vascular and fibrotic lesions in Fra-2 tg mice.
Pulmonary vasculopathy
Treatment with nilotinib strongly prevented the remodeling of pulmonary arteries (Fig.4B ) compared to vehicle-treated Fra-2 tg mice (Fig.4A ). The endothelial cell layer (vWF+) was not affected upon treatment with nilotinib ( Fig.4B ) compared to wt mice (Fig.4A) . Semiquantitative analysis showed that compared to vehicle-treated Fra-2 tg mice, in nilotinib treated Fra-2 tg mice both the thickness of vessel walls (median (Q1,Q3) 44 (32,59) vs. 22.5 (18, 28) μm, p<0.0001) (Fig.4C ) and the percentage of obliterated vessels (33 (13, 53) % vs. 0 (0,7) %, p=0.03) (Fig.4D) (Fig.4G ).
As expected, the expression of p-PDGFRβ (Fig.5B) , and also of PDGF-BB ( 
Discussion
To date, there is substantial evidence on several levels that SSc-PAH, though sharing similarities, substantially differs from IPAH and thus might warrant different therapeutic approaches. However, the development of targeted therapies is hampered by the lack of human biosamples of SSc patients and by the lack of suitable animal models for preclinical studies.
Our study suggests Fra-2 tg mice as a potential model for SSc-PAH. The comprehensive histological and immunohistochemical analysis showed that Fra-2 tg mice displayed many pathologic changes characteristic for the vascular remodeling in human SSc-PAH (6, 7, 18) . The model can however not be used to further delineate mechanisms underlying POV, as POV-specific features were not identified in our study. Besides vasculopathy, interstitial inflammation and fibrosis closely resembling human NSIP as the most common form of SSc-ILD could be observed. Fibroblastic foci and honeycombing, associated with UIP, were rarely detectable in our study, but were identified more frequently in a recent study (10) . This might be explained by the different background of Fra-2 tg mice, as the mice in this study were backcrossed from a mixed (C57BL/6×CBA) genetic background on a pure C57/Bl6 background.
However, besides allowing the evaluation of pathophysiologic mechanisms and in particular the interplay of pro-fibrotic and vascular processes, Fra-2 tg mice might also serve as a preclinical model for interventional proof of concept studies.
The tyrosine kinase inhibitor nilotinib by blocking PDGFR signaling prevented the development of both proliferative pulmonary vasculopathy and fibrosis in Fra-2 tg mice which argues for SSc-specific therapies of PH. Furthermore, our data support previous studies on PDGF as key mediator of vasculopathy in SSc-P(A)H (17) (18) (19) .
Inhibition of PDGF signaling, e. g. by tyrosine kinase inhibitors, might be an example of a promising future therapy for P(A)H (20) with particular evidence in SSc-PAH, as it targets vascular as well as fibrotic changes (21, 22) .
The role of Fra-2 as a potential key player for the development of (pulmonary)
vasculopathy and fibrosis in SSc should be addressed in further studies. Recent data demonstrated an increased expression of Fra-2 in lung biopsies from patients with UIP, NSIP and SSc-associated NSIP (10) . Based on previous data on microvasculopathy and dermal fibrosis in SSc patients (11, 23) , a recent study demonstrated substantial anti-fibrotic effects of AP-1 inhibition in different animal models of SSc (24) . Thus, Fra-2/AP-1 itself might represent an interesting molecular target for future SSc-specific therapies, even more so, since several pro-inflammatory chemokines and cytokines implicated in the pathogenesis of SSc were expressed in high levels in the lungs of Fra-2 tg mice including CXCL5, CCL2, IL-2, IL-4, IL-6 (10).
Inhibition of these downstream targets with currently available drugs might elucidate further treatment options. AP-1 is induced by growth factors, cytokines and oncoproteins which are involved in the proliferation, survival, differentiation and transformation of cells (25) . Whether Fra-2 related pathogenic changes in vivo might be accelerated by other factors such as pro-inflammatory stimuli or hypoxia (26) in pulmonary disease will have to be addressed in future studies.
Taken together, the model of Fra-2 tg mice is the first animal model that simultaneously displays major histopathological features of pulmonary SSc, e. g. pulmonary proliferative vasculopathy and interstitial fibrosis, which occur frequently together in patients with SSc and are associated with a high mortality. Fra-2 tg mice hold great promise to further delineate the pathophysiological links between vascular remodeling and fibrosis in pulmonary SSc and to identify potential specific molecular and cellular targets for intervention. This study also underlines a prominent role of PDGF in the pathophysiology of pulmonary SSc and suggests Fra-2 tg mice as a preclinical model for interventional proof of concept studies in pulmonary SSc.
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